{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:33:12Z","timestamp":1786365192212,"version":"build-2736575974"},"reference-count":76,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ValenzaBio"},{"name":"ACELYRIN"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","award":["EY031398"],"award-info":[{"award-number":["EY031398"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>In thyroid eye disease (TED), the connective tissue behind the eye becomes inflamed and expands, partly due to excessive deposition of hyaluronan (HA), which absorbs water, leading to osmotic swelling. Orbital fibroblasts (OFs) from patients with TED overexpress insulin-like growth factor 1 receptor (IGF-1R), a receptor that promotes cell survival, proliferation, and HA production. These processes contribute to orbital tissue remodeling and expansion, as well as to the inflammation and fibrosis characteristic of TED. Therapeutic options remain limited, highlighting the need for additional targeted therapies. Lonigutamab is a next-generation anti-IGF-1R monoclonal antibody that binds to a distinct epitope on IGF-1R with high affinity, eliciting a novel mechanism of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether lonigutamab inhibits HA production and characterize its mechanism of action using TED OFs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TED OFs were treated with lonigutamab in the presence or absence of IGF-1. HA was measured by ELISA and agarose gel electrophoresis. IGF-1R levels were assessed by flow cytometry and Western blot. The proteasome inhibitor MG132 and the lysosome\/autophagy inhibitor bafilomycin were used to probe lonigutamab-mediated degradation pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lonigutamab significantly reduced basal and IGF-1-induced HA production across all evaluated TED OF strains. Lonigutamab also decreased mature IGF-1R protein levels in a time- and dose-dependent manner by promoting IGF-1R internalization and subsequent degradation through proteasomal and lysosomal pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that lonigutamab suppresses HA production in TED OFs via efficient IGF-1R internalization and degradation, supporting its unique mechanism of action and potential as a therapeutic option for TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag299","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:41:42Z","timestamp":1784893302000},"source":"Crossref","is-referenced-by-count":0,"title":["Lonigutamab inhibits hyaluronan production by reducing IGF-1R levels in thyroid eye disease orbital fibroblasts"],"prefix":"10.1210","author":[{"given":"Elisa","family":"Roztocil","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farha","family":"Husain","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charkira C","family":"Patrick","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Thomas","sequence":"additional","affiliation":[{"name":"Sera Medicines, LLC , Boston, MA 02116 ,","place":["USA"]},{"name":"ValenzaBio, Inc. , Bethesda, MD 20817 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Mack","sequence":"additional","affiliation":[{"name":"ValenzaBio, Inc. , Bethesda, MD 20817 ,","place":["USA"]},{"name":"ACELYRIN, Inc. , Agoura Hills, CA 91301 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Nyborg","sequence":"additional","affiliation":[{"name":"ACELYRIN, Inc. , Agoura Hills, CA 91301 ,","place":["USA"]},{"name":"Alumis, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett D","family":"Welch","sequence":"additional","affiliation":[{"name":"ACELYRIN, Inc. , Agoura Hills, CA 91301 ,","place":["USA"]},{"name":"Alumis, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Feldon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]},{"name":"Center for Visual Sciences, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-5057","authenticated-orcid":false,"given":"Collynn F","family":"Woeller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]},{"name":"Center for Visual Sciences, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]},{"name":"Department of Environmental Medicine, School of Medicine and Dentistry, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"8","key":"2026081008145609400_dgag299-B1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2026081008145609400_dgag299-B2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of Graves\u2019 ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res"},{"issue":"3","key":"2026081008145609400_dgag299-B3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.survophthal.2021.08.010","article-title":"Thinking inside the box: current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease","volume":"67","author":"Gupta","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"2026081008145609400_dgag299-B4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2026081008145609400_dgag299-B5","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081008145609400_dgag299-B6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026081008145609400_dgag299-B7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature","volume":"9","author":"Munoz-Ortiz","year":"2020","journal-title":"Syst Rev"},{"issue":"1","key":"2026081008145609400_dgag299-B8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2026081008145609400_dgag299-B9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/ICU.0b013e3283131557","article-title":"The eye and thyroid disease","volume":"19","author":"Kuriyan","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"2026081008145609400_dgag299-B10","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"Suppl_1","key":"2026081008145609400_dgag299-B11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081008145609400_dgag299-B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12886-018-0679-4","article-title":"Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"2026081008145609400_dgag299-B13","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081008145609400_dgag299-B14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1632531","article-title":"Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves\u2019 orbitopathy","volume":"16","author":"Boutzios","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026081008145609400_dgag299-B15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bph.13693","article-title":"Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: studies in orbital fibroblasts in vitro","volume":"174","author":"Place","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2026081008145609400_dgag299-B16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/sjopt.sjopt_179_23","article-title":"Teprotumumab in thyroid eye disease","volume":"38","author":"Goldberg","year":"2024","journal-title":"Saudi J Ophthalmol"},{"issue":"Suppl_1","key":"2026081008145609400_dgag299-B17","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026081008145609400_dgag299-B18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/thy.2022.0172","article-title":"A survey on the management of thyroid eye disease among American and European Thyroid Association members","volume":"32","author":"Brito","year":"2022","journal-title":"Thyroid"},{"issue":"6","key":"2026081008145609400_dgag299-B19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/endrev\/bnae018","article-title":"Teprotumumab for the treatment of Thyroid eye disease","volume":"45","author":"Ugradar","year":"2024","journal-title":"Endocr Rev"},{"issue":"1","key":"2026081008145609400_dgag299-B20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12020-024-03852-x","article-title":"An observational study on the safety of teprotumumab based on FAERS database","volume":"85","author":"Wang","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"2026081008145609400_dgag299-B21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/clinem\/dgae417","article-title":"Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment","volume":"110","author":"Huang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026081008145609400_dgag299-B22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"2026081008145609400_dgag299-B23"},{"issue":"4","key":"2026081008145609400_dgag299-B24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"2026081008145609400_dgag299-B25","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/JME-17-0276","article-title":"IGF1 receptor and thyroid-associated ophthalmopathy","volume":"61","author":"Mohyi","year":"2018","journal-title":"J Mol Endocrinol"},{"issue":"19","key":"2026081008145609400_dgag299-B26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914882","article-title":"The IGF1 signaling pathway: from basic concepts to therapeutic opportunities","volume":"24","author":"Werner","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026081008145609400_dgag299-B27","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1038\/jid.2012.228","article-title":"Insulin-like growth factor-1 promotes wound healing in estrogen-deprived mice: new insights into cutaneous IGF-1R\/ERalpha cross talk","volume":"132","author":"Emmerson","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2026081008145609400_dgag299-B28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1161\/CIRCRESAHA.108.186742","article-title":"IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha\/CXCR4 signaling to promote myocardial repair","volume":"103","author":"Haider","year":"2008","journal-title":"Circ Res"},{"issue":"11","key":"2026081008145609400_dgag299-B29","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.1501237","article-title":"Myeloid cell-restricted insulin\/IGF-1 receptor deficiency protects against skin inflammation","volume":"195","author":"Knuever","year":"2015","journal-title":"J Immunol"},{"issue":"2","key":"2026081008145609400_dgag299-B30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/pr.109.002469","article-title":"Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?","volume":"62","author":"Smith","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2026081008145609400_dgag299-B31","doi-asserted-by":"crossref","DOI":"10.1038\/srep34373","article-title":"Single-cell analysis reveals IGF-1 potentiation of inhibition of the TGF-beta\/Smad pathway of fibrosis in human keratocytes in vitro","volume":"6","author":"Sarenac","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"2026081008145609400_dgag299-B32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2024.0529","article-title":"Targeting the aryl hydrocarbon receptor to attenuate IGF1R signaling in thyroid eye disease","volume":"35","author":"Roztocil","year":"2025","journal-title":"Thyroid"},{"issue":"3","key":"2026081008145609400_dgag299-B33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2026081008145609400_dgag299-B34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"6","key":"2026081008145609400_dgag299-B35","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"issue":"8","key":"2026081008145609400_dgag299-B36","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"2026081008145609400_dgag299-B37","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081008145609400_dgag299-B38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","article-title":"Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves\u2019 ophthalmopathy","volume":"142","author":"Dik","year":"2016","journal-title":"Exp Eye Res"},{"issue":"2","key":"2026081008145609400_dgag299-B39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/iovs.61.2.27","article-title":"Characteristics of hyaluronan synthesis inhibition by 4-methylumbelliferone in orbital fibroblasts","volume":"61","author":"Galgoczi","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2026081008145609400_dgag299-B40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1152\/physrev.00052.2009","article-title":"Hyaluronan as an immune regulator in human diseases","volume":"91","author":"Jiang","year":"2011","journal-title":"Physiol Rev"},{"issue":"6","key":"2026081008145609400_dgag299-B41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/gels11060406","article-title":"Agarose gel electrophoresis reveals the molecular weight distribution of hyaluronan produced by orbital fibroblasts","volume":"11","author":"Galgoczi","year":"2025","journal-title":"Gels"},{"issue":"2","key":"2026081008145609400_dgag299-B42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/en.2013-1890","article-title":"A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves\u2019 disease orbital cells","volume":"155","author":"Krieger","year":"2014","journal-title":"Endocrinology"},{"issue":"Suppl_1","key":"2026081008145609400_dgag299-B43","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It takes two to tango: IGF-I and TSH receptors in thyroid eye disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"2026081008145609400_dgag299-B44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.182352","article-title":"Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway","volume":"9","author":"Kim","year":"2024","journal-title":"JCI Insight"},{"issue":"29","key":"2026081008145609400_dgag299-B45","doi-asserted-by":"crossref","first-page":"22583","DOI":"10.1074\/jbc.M002915200","article-title":"Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1\/2 activation in COS-7 cells","volume":"275","author":"Roudabush","year":"2000","journal-title":"J Biol Chem"},{"issue":"6","key":"2026081008145609400_dgag299-B46","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy","volume":"9","author":"van der Veeken","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"2026081008145609400_dgag299-B47","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/ijc.28169","article-title":"Ligand-independent activation of MET through IGF-1\/IGF-1R signaling","volume":"133","author":"Varkaris","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"2026081008145609400_dgag299-B48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12865-024-00613-3","article-title":"Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"issue":"1","key":"2026081008145609400_dgag299-B49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/1535-7163.MCT-19-0219","article-title":"Efficacy of the antibody-drug conjugate W0101 in preclinical models of IGF-1 receptor overexpressing solid tumors","volume":"19","author":"Akla","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2026081008145609400_dgag299-B50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2025.102479","article-title":"Therapeutic advances in Graves\u2019 orbitopathy: from corticosteroids to targeted immunotherapy - insights from the TOGO and THRIVE trials","volume":"87","author":"Ladsous","year":"2026","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2026081008145609400_dgag299-B51","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2585616","article-title":"Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease","volume":"17","author":"Kaplan","year":"2025","journal-title":"MAbs"},{"issue":"1","key":"2026081008145609400_dgag299-B52","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1038\/s41598-020-65414-1","article-title":"The aryl hydrocarbon receptor pathway controls matrix metalloproteinase-1 and collagen levels in human orbital fibroblasts","volume":"10","author":"Roztocil","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"2026081008145609400_dgag299-B53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1096\/fj.14-257121","article-title":"Thy1 (CD90) controls adipogenesis by regulating activity of the Src family kinase, Fyn","volume":"29","author":"Woeller","year":"2015","journal-title":"FASEB J"},{"issue":"4","key":"2026081008145609400_dgag299-B54","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0002-9440(10)63488-8","article-title":"Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes","volume":"163","author":"Koumas","year":"2003","journal-title":"Am J Pathol"},{"issue":"9","key":"2026081008145609400_dgag299-B55","first-page":"2620","article-title":"Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts","volume":"80","author":"Smith","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"45","key":"2026081008145609400_dgag299-B56","article-title":"PDGFRalpha(+)DPP4(+) fibroblasts-macrophage crosstalk induces orbital fibrosis in treatment-resistant thyroid eye disease via the GAS6-AXL pathway","volume":"12","author":"Cheng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"2026081008145609400_dgag299-B57","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18535","article-title":"miR-101-3p suppresses proliferation of orbital fibroblasts by targeting pentraxin-3 in thyroid eye disease","volume":"12","author":"Zhu","year":"2024","journal-title":"PeerJ"},{"issue":"4","key":"2026081008145609400_dgag299-B58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"29","key":"2026081008145609400_dgag299-B59","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1016\/S0021-9258(18)54996-6","article-title":"Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors","volume":"266","author":"Schumacher","year":"1991","journal-title":"J Biol Chem"},{"issue":"31","key":"2026081008145609400_dgag299-B60","doi-asserted-by":"crossref","first-page":"16267","DOI":"10.1016\/S0021-9258(18)37588-4","article-title":"The structural basis for insulin-like growth factor I receptor high affinity binding","volume":"263","author":"Tollefsen","year":"1988","journal-title":"J Biol Chem"},{"issue":"13","key":"2026081008145609400_dgag299-B61","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1074\/jbc.272.13.8189","article-title":"Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change","volume":"272","author":"Jansson","year":"1997","journal-title":"J Biol Chem"},{"issue":"3","key":"2026081008145609400_dgag299-B62","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.0014-2956.2001.02735.x","article-title":"Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis","volume":"269","author":"Forbes","year":"2002","journal-title":"Eur J Biochem"},{"issue":"8","key":"2026081008145609400_dgag299-B63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/cells8080895","article-title":"Therapeutic targeting of the IGF axis","volume":"8","author":"Osher","year":"2019","journal-title":"Cells"},{"issue":"10","key":"2026081008145609400_dgag299-B64","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1167\/iovs.15-16580","article-title":"Mesenchymal stem cell-like properties of orbital fibroblasts in Graves\u2019 orbitopathy","volume":"56","author":"Kozdon","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026081008145609400_dgag299-B65","article-title":"Controlled signaling-insulin-like growth factor receptor endocytosis and presence at intracellular compartments","volume":"11","author":"Rieger","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026081008145609400_dgag299-B66","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.1128\/MCB.19.10.7203","article-title":"Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis","volume":"19","author":"Peruzzi","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"14","key":"2026081008145609400_dgag299-B67","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1073\/pnas.1431613100","article-title":"Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor","volume":"100","author":"Girnita","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2026081008145609400_dgag299-B68","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00018-013-1514-y","article-title":"Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation","volume":"71","author":"Girnita","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2026081008145609400_dgag299-B69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.cellbio.23.090506.123337","article-title":"Hyaluronan in tissue injury and repair","volume":"23","author":"Jiang","year":"2007","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"2026081008145609400_dgag299-B70","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1210\/clinem\/dgaa684","article-title":"Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy","volume":"106","author":"Fernando","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026081008145609400_dgag299-B71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000511538","article-title":"Targeting TSH and IGF-1 receptors to treat thyroid eye disease","volume":"9","author":"Neumann","year":"2020","journal-title":"Eur Thyroid J"},{"key":"2026081008145609400_dgag299-B72","author":"Li"},{"key":"2026081008145609400_dgag299-B73","author":"Truong"},{"key":"2026081008145609400_dgag299-B74","author":"Kahaly"},{"key":"2026081008145609400_dgag299-B75","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1211473","article-title":"Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease","volume":"14","author":"Gulbins","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026081008145609400_dgag299-B76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/a-2186-5548","article-title":"Current therapeutic approaches for Graves\u2019 orbitopathy - are targeted therapies the future?","volume":"241","author":"Eckstein","year":"2024","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag299\/70160351\/dgag299.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag299\/70160351\/dgag299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:15:10Z","timestamp":1786364110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag299\/8742272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag299","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"dgag299"}}